Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMA

ImageneBio Inc

Healthcare · Biotechnology

$4.24

Down-$0.02 (-0.47%)

Updated Oct 10, 2026, 10:44 AM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
72.57M
P/E ratio
-10.19
Dividend yield
0.00%
52-week range
$3.90 – $6.64
Volume
8.12K
Avg. volume
69.97K

Price performance · IMA

IMA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

IMA closed at $4.24 after 21 trading sessions, down 16.54% for the selected period.

Last close
$4.24
Period change
-16.54%
Period low
$4.24
Period high
$5.08
Daily close
View OHLC price history
IMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$4.17$4.31$3.90$4.248.12K
Oct 8, 2026$4.48$4.48$4.00$4.2630.08K
Oct 7, 2026$4.60$4.61$4.60$4.612.24K
Oct 6, 2026$4.70$4.72$4.60$4.6013.74K
Oct 5, 2026$4.6016$4.73$4.6016$4.708.53K
Oct 2, 2026$4.685$4.685$4.5569$4.607.83K
Oct 1, 2026$4.60$4.67$4.58$4.580111.83K
Sep 30, 2026$4.58$4.63$4.58$4.589.36K
Sep 29, 2026$4.61$4.615$4.57$4.587.26K
Sep 28, 2026$4.845$4.845$4.64$4.642.19K
Sep 25, 2026$4.70$4.81$4.70$4.7217.83K
Sep 24, 2026$4.82$4.82$4.65$4.663.69K
Sep 23, 2026$4.95$4.975$4.81$4.841.48K
Sep 22, 2026$4.765$5.02$4.765$4.858.46K
Sep 21, 2026$4.80$5.0999$4.80$4.8123.92K
Sep 18, 2026$5.18$5.24$4.64$4.8977.05K
Sep 17, 2026$5.21$5.28$4.99$5.0222.82K
Sep 16, 2026$5.175$5.18$4.88$4.9320.35K
Sep 15, 2026$4.99$5.19$4.7622$4.9214.25K
Sep 14, 2026$5.22$5.39$4.995$5.0014.98K
Sep 11, 2026$5.08$5.14$4.925$5.088.05K

Latest IMA news

The latest Smart Investors Daily articles mentioning IMA.

Stock researchCompany · Overview

IMA research

Overview

Company profile and research snapshot.

Company profile

ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.33
Implied upside
—
Analysts
—
IMA recent ratings
DateFirmRatingTarget
Aug 21, 2026HC Wainwright & Co.Buy—
May 11, 2026WedbushUnderperform—
Oct 24, 2025Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new empl

Yahoo · Sep 8, 2026

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings. H.C. Wainwright 28th Annual Global Investment Conference in New YorkFireside Chat: Monday, Sept. 14, 2026, 3:30pm ETWebcast linked here and

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By